Modified DLI (third party health donor double negative T cells) for the treatment of myeloid malignancies relapse after allogeneic hematopoietic stem cell transplantation: a single center clinical research
Latest Information Update: 10 Jan 2021
At a glance
- Drugs Double negative T-cell therapy (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus First in man; Therapeutic Use
- 10 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology